423 related articles for article (PubMed ID: 24197130)
1. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
Alizadeh D; Trad M; Hanke NT; Larmonier CB; Janikashvili N; Bonnotte B; Katsanis E; Larmonier N
Cancer Res; 2014 Jan; 74(1):104-18. PubMed ID: 24197130
[TBL] [Abstract][Full Text] [Related]
2. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
3. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
[TBL] [Abstract][Full Text] [Related]
4. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of myeloid-derived suppressor cells in the tumor microenvironment by low-dose doxorubicin to improve immune efficacy in murine neuroblastoma.
Xu WL; Shi BJ; Li SL; Yu FX; Guo LN; Li M; Hu ZG; Li GX; Zhou H
Chin Med J (Engl); 2020 Dec; 134(3):334-343. PubMed ID: 33278092
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.
Shime H; Kojima A; Maruyama A; Saito Y; Oshiumi H; Matsumoto M; Seya T
J Innate Immun; 2014; 6(3):293-305. PubMed ID: 24192491
[TBL] [Abstract][Full Text] [Related]
8. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
9. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
Li H; Han Y; Guo Q; Zhang M; Cao X
J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
[TBL] [Abstract][Full Text] [Related]
10. A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response.
Chakraborty P; Das S; Banerjee K; Sinha A; Roy S; Chatterjee M; Choudhuri SK
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):165-75. PubMed ID: 24611750
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
12. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.
Kmieciak M; Basu D; Payne KK; Toor A; Yacoub A; Wang XY; Smith L; Bear HD; Manjili MH
J Immunol; 2011 Jul; 187(2):708-17. PubMed ID: 21670315
[TBL] [Abstract][Full Text] [Related]
13. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.
Tsukamoto H; Nishikata R; Senju S; Nishimura Y
Cancer Immunol Res; 2013 Jul; 1(1):64-76. PubMed ID: 24777249
[TBL] [Abstract][Full Text] [Related]
15. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells.
Horlad H; Fujiwara Y; Takemura K; Ohnishi K; Ikeda T; Tsukamoto H; Mizuta H; Nishimura Y; Takeya M; Komohara Y
Mol Nutr Food Res; 2013 Jun; 57(6):1046-54. PubMed ID: 23417831
[TBL] [Abstract][Full Text] [Related]
16. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model.
Huang X; Cui S; Shu Y
Immunol Res; 2016 Feb; 64(1):160-70. PubMed ID: 26590944
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
20. Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer.
Forghani P; Waller EK
Breast Cancer Res Treat; 2015 Aug; 153(1):21-30. PubMed ID: 26208484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
